Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

被引：0
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 02期
关键词：
FEATURES;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 5 条
  • [1] [Anonymous], 2018, ADC
  • [2] Kim YH, 2018, BLOOD S1, V132
  • [3] Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
    Prince, H. Miles
    Kim, Youn H.
    Horwitz, Steven M.
    Dummer, Reinhard
    Scarisbrick, Julia
    Quaglino, Pietro
    Zinzani, Pier Luigi
    Wolter, Pascal
    Sanches, Jose A.
    Ortiz-Romero, Pablo L.
    Akilov, Oleg E.
    Geskin, Larisa
    Trotman, Judith
    Taylor, Kerry
    Dalle, Stephane
    Weichenthal, Michael
    Walewski, Jan
    Fisher, David
    Dreno, Brigitte
    Stadler, Rudolf
    Feldman, Tatyana
    Kuzel, Timothy M.
    Wang, Yinghui
    Palanca-Wessels, Maria Corinna
    Zagadailov, Erin
    Trepicchio, William L.
    Zhang, Wenwen
    Lin, Hui-Min
    Liu, Yi
    Huebner, Dirk
    Little, Meredith
    Whittaker, Sean
    Duvic, Madeleine
    [J]. LANCET, 2017, 390 (10094) : 555 - 566
  • [4] Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors
    Pulitzer, Melissa
    Myskowski, Patricia L.
    Horwitz, Steven M.
    Querfeld, Christiane
    Connolly, Brian
    Li, Janet
    Murali, Rajmohan
    [J]. PATHOLOGY, 2014, 46 (07) : 610 - 616
  • [5] Vergier B, 2000, BLOOD, V95, P2212
1